Filipe Pereira

Filipe Pereira is a Professor and Wallenberg Fellow in Molecular Medicine at Lund University, where Filipe leads a research team focused on immunology, stem cells, and cellular reprogramming. Pereira was previously promoted to Associate Professor with tenure and has contributed significantly to cancer immunotherapy through a research program supported by prestigious grants. As a co-founder and Head of Innovation at Asgard Therapeutics, Pereira is pioneering dendritic cell reprogramming to enhance immune system responses against cancer. In addition to an independent research group at the University of Coimbra, Pereira serves as Editor in Chief of the journal Cellular Reprogramming. Previously, Pereira co-founded BRT Blood Reprogramming Technologies, carried out postdoctoral research at prominent institutions, and earned a PhD from Imperial College London.